The Relation of Soluble Klotho with Cardiovascular Disease, Chronic Kidney Disease Progression, and Blood Pressure in the Systolic Blood Pressure Intervention Trial
收缩压干预试验中可溶性 Klotho 与心血管疾病、慢性肾病进展和血压的关系
基本信息
- 批准号:10451512
- 负责人:
- 金额:$ 29.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-15 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:Acute Renal Failure with Renal Papillary NecrosisAddressAffectAlbuminuriaAttenuatedBiological AssayBiological MarkersBiologyBloodBlood PressureCardiacCardiovascular DiseasesCause of DeathCell MaintenanceCessation of lifeChronic Kidney FailureClinicalClinical DataClinical ResearchCommunitiesDataDevelopmentDiseaseDisease ProgressionEnrollmentEnzyme-Linked Immunosorbent AssayEtiologyEventExhibitsFibroblast Growth FactorFibrosisFoundationsFunctional disorderFutureGene ExpressionGenesGlomerular Filtration RateHealthHeartHeart HypertrophyHumanHypertensionImmunoprecipitationImpairmentIndividualInjuryInjury to KidneyIntegral Membrane ProteinInterventionIntervention TrialKidneyKidney DiseasesKnockout MiceMeasurementMeasuresMetabolismMineralsModelingOutcomeOxidative StressParticipantPathologicPatientsPerformancePersonsPilot ProjectsProductionProtocols documentationRandomizedRecoveryRenal functionRenal tubule structureReportingReproducibilityResearchRisk FactorsRodentRodent ModelRoleSamplingSerumSourceSpecific qualifier valueSpecimenTherapeuticTherapeutic AgentsTherapeutic InterventionTimeTranslational ResearchTubular formationUrineVascular calcificationarmblood pressure controlblood pressure interventioncardiovascular disorder riskcardiovascular risk factorclinical riskcohortcoronary fibrosisfibroblast growth factor 23high riskhuman studymortalitynoveloverexpressionpre-clinicalpreclinical studypreventrenal damagerepairedrisk stratificationtrial comparing
项目摘要
ABSTRACT
Soluble α-klotho (“Klotho”) has systemic effects in maintenance of cell health including reduction of oxidative
stress and fibrosis in the heart and kidney. Kidney tubules are the primary source of circulating (soluble) klotho
and therefore the development of chronic kidney disease (CKD) results in klotho deficiency. Klotho deficiency
may also paradoxically contribute to CKD progression. Rodent models of klotho deficiency display vulnerability
to kidney injury and progression of kidney disease, while administration of exogenous klotho attenuates kidney
damage and disease progression. Klotho deficiency may also contribute to excess cardiovascular disease
(CVD) risk in CKD as klotho knockout mice display vascular calcification and pathological cardiac remodeling
with cardiac hypertrophy and fibrosis. Further, blood pressure (BP) may influence klotho levels as preclinical
data show that multiple models of hypertension all result in klotho deficiency. Thus far, the majority of clinical
studies examining soluble klotho have relied primarily on a single commercial source of ELISA. There are
concerns about the performance and reproducibility of this assay as the clinical data have been inconsistent.
Some studies have reported no relationship or higher levels of soluble klotho with reduced kidney function,
while others have shown a parallel decline in klotho and kidney function. This discrepancy has hindered
widespread measurement of klotho in large-scale human studies and has led to a paucity of quality data
examining the role of klotho in human CKD. Similarly, there are no longitudinal data on changes in klotho over
time in CKD. In a pilot project using samples from the Systolic Blood Pressure Intervention Trial (SPRINT) we
compared the most widely used commercial ELISA with an immunoprecipitation-immunoblot (IP-IB) assay, and
found that the IP-IB assay exhibited superior performance. Subsequently, we hope to address the current lack
of high quality human studies examining soluble klotho as a risk factor for CVD and CKD progression. SPRINT
is the ideal cohort to answer these questions as the trial enrolled 2646 participants with CKD and has detailed
CVD and kidney outcomes. This cohort is also well-suited to examine the patient-specific and disease-specific
clinical factors that may impact longitudinal changes in soluble klotho including: the intensive vs. standard
blood pressure control intervention, measures of mineral metabolism including FGF-23, and measures of
kidney tubular injury/health. We propose to measure baseline serum and urine klotho concentrations in 2646
SPRINT participants with CKD at baseline as well as in a pre-specified subset of 1000 persons at year 1 and
year 4 to: 1) compare the IP-IB assay with the commercial klotho ELISA; 2) determine the association of klotho
with CVD events, death, and CKD progression; and 3) identify the clinical factors that influence longitudinal
changes in klotho including intensive vs. standard BP control, markers of mineral metabolism and/or kidney
tubular health. Such data can collectively set the stage for future klotho interventional trials, inform clinical risk-
stratification models and provide a foundation for translational research in klotho biology and therapeutics.
摘要
可溶性α-klotho(“Klotho”)在维持细胞健康方面具有全身性作用,包括减少细胞内的氧化应激。
心脏和肾脏的压力和纤维化。肾小管是循环(可溶性)klotho的主要来源
因此慢性肾病(CKD)的发展导致Klotho缺乏。Klotho缺乏症
也可能自相矛盾地促进CKD进展。klotho缺陷的啮齿动物模型显示脆弱性
肾损伤和肾脏疾病进展,而外源性klotho的施用减弱了肾脏损伤和肾脏疾病进展。
损伤和疾病进展。Klotho缺乏症也可能导致过多的心血管疾病
(CVD)klotho基因敲除小鼠显示血管钙化和病理性心脏重塑,
心脏肥大和纤维化此外,血压(BP)可能会影响klotho水平,如临床前
数据显示,多种高血压模式均导致klotho缺乏症。到目前为止,大多数临床
检测可溶性Klotho的研究主要依赖于ELISA的单一商业来源。有
由于临床数据不一致,因此对该测定的性能和重现性存在担忧。
一些研究报告称,可溶性klotho与肾功能下降没有关系或水平较高,
而其他人则表现出klotho和肾功能的平行下降。这种差异阻碍了
在大规模的人类研究中广泛测量klotho,导致缺乏高质量的数据
研究klotho在人类CKD中的作用。同样,也没有关于klotho变化的纵向数据,
CKD时间在一个使用来自收缩压干预试验(SPRINT)样本的试点项目中,
将最广泛使用的商业ELISA与免疫沉淀-免疫印迹(IP-IB)测定进行比较,
发现IP-IB测定法表现出优越的上级性能。随后,我们希望解决目前缺乏
高质量的人类研究,检查可溶性klotho作为CVD和CKD进展的风险因素。SPRINT
是回答这些问题的理想队列,因为该试验招募了2646名CKD参与者,并详细介绍了
CVD和肾脏结局。该队列也非常适合检查患者特异性和疾病特异性
可能影响可溶性klotho纵向变化的临床因素包括:强化与标准
血压控制干预,包括FGF-23在内的矿物质代谢的测量,以及
肾小管损伤/健康。我们建议在2646名受试者中测量基线血清和尿液klotho浓度。
基线时患有CKD的SPRINT参与者以及第1年时预先指定的1000人亚组,
第4年:1)比较IP-IB测定与商业klotho ELISA; 2)确定klotho
CVD事件、死亡和CKD进展;以及3)确定影响纵向
klotho的变化,包括强化与标准BP控制、矿物质代谢和/或肾脏标志物
管健康。这些数据可以共同为未来的klotho干预性试验奠定基础,告知临床风险-
分层模型,并为klotho生物学和治疗学的转化研究提供基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Alan Drew其他文献
David Alan Drew的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Alan Drew', 18)}}的其他基金
The Relation of Soluble Klotho with Cardiovascular Disease, Chronic Kidney Disease Progression, and Blood Pressure in the Systolic Blood Pressure Intervention Trial
收缩压干预试验中可溶性 Klotho 与心血管疾病、慢性肾病进展和血压的关系
- 批准号:
10180234 - 财政年份:2021
- 资助金额:
$ 29.89万 - 项目类别:
The Relation of Soluble Klotho with Cardiovascular Disease, Chronic Kidney Disease Progression, and Blood Pressure in the Systolic Blood Pressure Intervention Trial
收缩压干预试验中可溶性 Klotho 与心血管疾病、慢性肾病进展和血压的关系
- 批准号:
10618989 - 财政年份:2021
- 资助金额:
$ 29.89万 - 项目类别:
The association of FGF-23 and Klotho with cognitive impairment and cerebrovascular disease in chronic kidney disease
FGF-23和Klotho与慢性肾脏病认知障碍和脑血管疾病的关系
- 批准号:
9304203 - 财政年份:2016
- 资助金额:
$ 29.89万 - 项目类别:
The association of FGF-23 and Klotho with cognitive impairment and cerebrovascular disease in chronic kidney disease
FGF-23和Klotho与慢性肾脏病认知障碍和脑血管疾病的关系
- 批准号:
9923642 - 财政年份:2016
- 资助金额:
$ 29.89万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 29.89万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 29.89万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 29.89万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 29.89万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 29.89万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 29.89万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 29.89万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 29.89万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 29.89万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 29.89万 - 项目类别:
Research Grant